Keyword: Harvoni

Gilead's promotion of Andrew Dickinson, and a fresh licensing deal, could signal that Gilead's looking outside its own walls for growth opportunities.

Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'

Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.

A Merck attorney who provided false testimony tainted the company's case, an appeals court ruled, and cost the company $200 million.

A host of challenges that drove Gilead's revenues down 14% last year didn’t stop its board from boosting the CEO’s pay package to $15.4 million.

In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.

Gilead's executive v.p. of worldwide commercial operations is unexpectedly retiring, at a time when the company is facing challenges across its infectious-disease and oncology portfolios.

Look out, Amgen, Allergan, et al. PBMs are eyeing your forthcoming meds for pricing pressure—and as hep C drugmakers know, consequences can be brutal.

The latest victory in a years-long hepatitis C patent battle between Gilead Sciences and Merck goes to Gilead.